PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 35352204-6 2022 It was observed that the expressions of NF-kappaB, TNF-alpha, IL-6, JAK2 and STAT3 in the inflammatory pathway increased after VPA administration, while RUT treatment decreased the levels of these markers. Valproic Acid 127-130 tumor necrosis factor Rattus norvegicus 51-60 34225559-7 2021 IL-1 level was found to be significantly lower in the benidipine 4 mg/kg group, and TNF-alpha was lower in the group given valproic acid+benidipine 2 mg/kg (p<0.05). Valproic Acid 123-136 tumor necrosis factor Rattus norvegicus 84-93 35543257-9 2022 SV administration also caused the upregulation of proinflammatory markers such as tumor necrosis factor alpha, c-Jun N-terminal kinase, nuclear factor kappa B, cyclooxygenase-2 and Interleukin 6 expressions in liver tissue. Valproic Acid 0-2 tumor necrosis factor Rattus norvegicus 82-109 34135667-8 2021 VPA also exhibited an anti-inflammatory effect as its treatment resulted in the reduction of tumor necrosis factor-alpha (TNF-alpha). Valproic Acid 0-3 tumor necrosis factor Rattus norvegicus 93-120 34135667-8 2021 VPA also exhibited an anti-inflammatory effect as its treatment resulted in the reduction of tumor necrosis factor-alpha (TNF-alpha). Valproic Acid 0-3 tumor necrosis factor Rattus norvegicus 122-131 34135667-10 2021 During the combined therapy, ASTA potentiated the antiepileptic effect of the VPA by reducing the oxidative stress and TNF-alpha as well as increased the glutathione (GSH) levels. Valproic Acid 78-81 tumor necrosis factor Rattus norvegicus 119-128 30769127-8 2019 Also, prenatal VPA treated rats have shown higher levels of oxidative stress (increased in thiobarbituric acid reactive species and decreased in reduced glutathione level) and inflammation (increased in interleukin-6, tumor necrosis factor-alpha and decreased in interleukin-10) in the cerebellum, brainstem and prefrontal cortex. Valproic Acid 15-18 tumor necrosis factor Rattus norvegicus 218-245 34048873-6 2021 The mRNA expression level of TNF-alpha also increased in hypoxia groups and valproic acid (VPA) group. Valproic Acid 76-89 tumor necrosis factor Rattus norvegicus 29-38 34048873-6 2021 The mRNA expression level of TNF-alpha also increased in hypoxia groups and valproic acid (VPA) group. Valproic Acid 91-94 tumor necrosis factor Rattus norvegicus 29-38 34054811-2 2021 Here, by two models of a primary rat breast cancer and cell co-culture, we demonstrated that valproic acid (VPA) and its derivative (HPTA) are effective immune activators for RT to inhibit tumor growth by inducing myeloid-derived macrophages and polarizing them toward the M1 phenotype, thus elevate the expression of cytokines such as IL-12, IL-6, IFN-gamma and TNF-alpha during the early stage of the combination treatment. Valproic Acid 93-106 tumor necrosis factor Rattus norvegicus 363-372 34054811-2 2021 Here, by two models of a primary rat breast cancer and cell co-culture, we demonstrated that valproic acid (VPA) and its derivative (HPTA) are effective immune activators for RT to inhibit tumor growth by inducing myeloid-derived macrophages and polarizing them toward the M1 phenotype, thus elevate the expression of cytokines such as IL-12, IL-6, IFN-gamma and TNF-alpha during the early stage of the combination treatment. Valproic Acid 108-111 tumor necrosis factor Rattus norvegicus 363-372 33421931-7 2021 VPA exerted anti-inflammatory effects by downregulating proinflammatory cytokines (tumor necrosis factor-alpha, cytokines interleukin-1beta, cytokines interleukin-6; TNF-alpha, IL-1beta, and IL-6) and upregulating anti-inflammatory cytokines (transforming growth factor-beta, cytokines interleukin-10, cytokines interleukin-4; TGF-beta, IL-10 and IL-4). Valproic Acid 0-3 tumor necrosis factor Rattus norvegicus 83-110 33421931-7 2021 VPA exerted anti-inflammatory effects by downregulating proinflammatory cytokines (tumor necrosis factor-alpha, cytokines interleukin-1beta, cytokines interleukin-6; TNF-alpha, IL-1beta, and IL-6) and upregulating anti-inflammatory cytokines (transforming growth factor-beta, cytokines interleukin-10, cytokines interleukin-4; TGF-beta, IL-10 and IL-4). Valproic Acid 0-3 tumor necrosis factor Rattus norvegicus 166-175 33275538-7 2021 RESULTS: Rats that received VPA showed leucopenia, thrombocytopenia, a significant decrease of SOD, glutathione, Nrf2, and Sirt1, besides a significant increase of MDA and TNF alpha. Valproic Acid 28-31 tumor necrosis factor Rattus norvegicus 172-181 32139333-8 2020 At the same time, valproic acid administration resulted in marked elevation in hydroxyproline, TNF-alpha production and NF-kB expression. Valproic Acid 18-31 tumor necrosis factor Rattus norvegicus 95-104 31624995-11 2020 VPA administration significantly increased the levels of alpha-GST, MDA, NF-kappaB and of IL-1beta, TNF-alpha gene expression in the liver compared to Group C. Moreover, vacuolization, hydropic degeneration, inflammatory cell infiltration, and sinusoidal congestion were commonly detected in the VPA-treated group along with the highest apoptotic index (TUNEL staining) values. Valproic Acid 0-3 tumor necrosis factor Rattus norvegicus 100-109 30405207-7 2018 VPA lowered CCI-induced inflammatory proteins (pNFkappaB, iNOS and COX-2), pro-apoptotic proteins (pAKT/AKT and pGSK-3beta/GSK-3beta), proinflammatory cytokines (TNF-alpha and IL-1beta) and nuclear pNFkappaB activation in the SN, DRG and SC in CCI rats. Valproic Acid 0-3 tumor necrosis factor Rattus norvegicus 162-171 28040845-10 2017 Treatment with sodium valproate at the doses of 100 and 300 mg/Kg) decreased the MPO activity and colonic concentrations of IL-1beta, IL-6 and TNF-alpha. Valproic Acid 15-31 tumor necrosis factor Rattus norvegicus 143-152 27526269-9 2016 Valproic acid and/or butyrate resulted in significant improvement of the body weight gain, oxidative stress, TGF-beta1, IL-6, TNF-alpha, hydroxyproline and BAL cellularity together with significant improvement of the histopathological and immunohistochemical picture. Valproic Acid 0-13 tumor necrosis factor Rattus norvegicus 126-135 24430491-12 2014 Moreover, VPA significantly suppressed myeloperoxidase activity (marker of neutrophil-mediated oxidative damage) and inhibited levels of proinflammatory cytokine tumor necrosis factor alpha and interleukin 6 in the serum and peritoneal cavity. Valproic Acid 10-13 tumor necrosis factor Rattus norvegicus 162-189 23584602-10 2013 In addition, the anti-inflammatory action of VA was potentiated by pentoxifylline (a phosphodiesterase inhibitor, known to inhibit TNF-alpha production), but not by sodium butyrate or by suberoylanilide hydroxamic acid (SAHA), nonspecific and specific inhibitors, respectively, of histone deacetylase. Valproic Acid 45-47 tumor necrosis factor Rattus norvegicus 131-140 30736910-9 2019 Treating the injured slices with valproic acid resulted in a significant decrease of TNF-alpha and increase of BDNF expression. Valproic Acid 33-46 tumor necrosis factor Rattus norvegicus 85-94 30004275-6 2018 Valproic acid (VPA)-induced autistic rats showed severe changes in oxidative stress markers, neurotransmitters and inflammatory cytokines, besides genotoxic manifestation of expression of tumour necrosis factor (TNF)-alpha, Bax and caspase-3. Valproic Acid 0-13 tumor necrosis factor Rattus norvegicus 188-222 30004275-6 2018 Valproic acid (VPA)-induced autistic rats showed severe changes in oxidative stress markers, neurotransmitters and inflammatory cytokines, besides genotoxic manifestation of expression of tumour necrosis factor (TNF)-alpha, Bax and caspase-3. Valproic Acid 15-18 tumor necrosis factor Rattus norvegicus 188-222 22344726-2 2012 This study was designed to evaluate the effect of valproic acid (VPA) and progesterone (P4) in a rat model of endometriosis on serum tumor necrosis factor-alpha (TNF-alpha) levels, hot plate and tail-flick latencies, lesion size, and body weight. Valproic Acid 50-63 tumor necrosis factor Rattus norvegicus 133-160 21571092-4 2011 VPA (500mg/kg p.o., for 2weeks) caused rat hepatotoxicity that was manifested as notable (2- to 4-fold) rise in serum liver enzymes (GGT, ALT, and ALP), increased hepatic levels of lipid peroxides and TNF-alpha (3- and 7-fold) and activity of myeloperoxidase (MPO, 4-fold), lowering of serum albumin (42%), and depletion of liver reduced glutathione (GSH, 36%). Valproic Acid 0-3 tumor necrosis factor Rattus norvegicus 201-210 15790540-8 2005 Specifically, LPS-induced increase in the release of TNFa, NO, and intracellular reactive oxygen species was markedly reduced in cultures pretreated with VPA. Valproic Acid 154-157 tumor necrosis factor Rattus norvegicus 53-57